-
Algeta agreements triggers milestone payment from Bayer Schering Pharma
Algeta ASA has concluded two agreements for the manufacture and supply of Alpharadin for future commercial sale. The signing of these agreements triggers a EUR 5 million milestone payment from Bayer Schering Pharma, Algeta's development and commercial partner for Alpharadin.
>> Read more26.07.10 -
FDA approves Cysview for detection of bladder cancer
The US Food and Drug Administration (FDA) has approved Cysview(TM), a fluorescence-based procedure for detection of papillary bladder cancer. Photocure will now receive a 10 million milestone payment from GE Healthcare, its US licensee, and will be eligible for undisclosed royalties once the product has been launched.
>> Read more31.05.10 -
Patent granted to Biotec Pharmacon in USA
Biotec Pharmacon reports that one of the company's patent applications referring to a combination therapy for cancer treatment has been granted in USA.
The patent is a composition patent protecting combinations of Biotec Pharmacon's proprietary compound soluble yeast beta-glucan (SBG) as an adjuvant together with monoclonal antibodies for treatment of cancer.>> Read more28.05.10 -
Photocure announces results from phase II study with Visonac
Photocure ASA announces results from its phase II study in acne with Visonac(TM) in combination with its new full face acne lamp. The efficacy results received in the last phase II study in acne with a simplified VisonacTM procedure were not as good as phase II results previously obtained with VisonacTM.
>> Read more28.05.10 -
Photocure wins patent case against the US Patent and Trademark Office
The US Federal Circuit Court of Appeals (CAFC) has upheld a lower court's decision stating that the United States Patent and Trademark Office's interpretation of the law when refusing Photocure's request for patent term extension was not reasonable.
>> Read more12.05.10 -
Algeta selects new Board of Directors
Dr. Judith Hemberger and Dr. Kapil Dhingra were elected to Algeta's Board of Directors as Non-executive Directors at the Company's annual general meeting held in Oslo on 22 April 2010.
>> Read more28.04.10 -
Affitech signs strategic alliance with Russian partner
Affitech A/S, the antibody medicines company, has entered into a research and development collaboration with LLC NTS Plus (Russia). Simultaneously, Trans Nova Investments Limited, with the key beneficiary being Mr Viktor Kharitonin, Chairman of Pharmstandard, has made an equity investment of €20.9m in Affitech.
>> Read more22.04.10 -
European expert panel recommends Hexvix
Despite considerable positive evidence, the use of Hexvix has historically differed widely from country to country and between clinics. European recommendations from a consensus group have now been published, which may make the use of Hexvix-guided fluorescence cystoscopy more unison in Europe.
>> Read more22.04.10 -
NorDiag's kick start for an exciting 2010
NorDiag's strong growth for the Company's core business continued in 2009, giving a total operating revenue growth of 43 % for 2009 compared to 2008. The restructuring of the Company is completed and the operation is financially secured towards a break-even quarter in 2011. "2010 will be an exciting year for NorDiag," comments CEO Mårten Wigstøl.
>> Read more19.02.10 -
A transformational year for Algeta ASA
"2009 was a transformational year for Algeta during which we successfully delivered a number of major milestones in progressing towards our objective of creating a focused oncology company," said Andrew Kay, Algeta's President and CEO. The results for the last quarter and full year 2009 were presented in Oslo Friday.
>> Read more19.02.10
Norwegian Bioindustry Association
Middelthuns gt. 27, Postboks 7072 Majorstuen, NO-0306 Oslo Tel: +47 23 08 88 00 / +47 23 08 88 18 / +47 91 10 54 91 Email: biotek@norskindustri.no Fax: +47 23 08 88 98